Enpaxiq: Withdrawal of the marketing authorisation application


On 20 February 2017, CTI BioPharma officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Enpaxiq, for treating patients with an enlarged spleen or other symptoms of myelofibrosis.

  • List item

    Questions and answers on the withdrawal of the marketing authorisation application for Enpaxiq (pacritinib) (PDF/69.02 KB)

    First published: 24/03/2017
    Last updated: 24/03/2017

  • Key facts

    Product number
    Date of withdrawal
    Company making the application
    CTI Life Sciences Limited
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating